Q4 2024 Earnings Call Transcript February 28, 2025 Operator: Welcome everyone to Natera’s 2024 Fourth Quarter Financial ...

Genetic testing company Natera (NASDAQ:NTRA). reported Q4 CY2024 results , with sales up 53% year on year to $476.1 million.

In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on Natera (NTRA – Research Report). The company’s shares ...

BTIG analyst Mark Massaro raised the firm’s price target on Natera (NTRA) to $190 from $185 and keeps a Buy rating on the shares. The company ...

A federal judge on Monday threw out a $96 million jury verdict against genetic testing company CareDX that rival Natera had ...

Natera Inc (NTRA) reports a 53% revenue surge and outlines strategic initiatives amidst competitive pressures and ...

Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for ...

The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high- ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid ...

Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsMike Brophy - Chief Financial ...

Welcome, everyone, to Natera's 2024 fourth-quarter financial results conference call. (Operator Instructions) As a reminder, this conference call is being recorded, today, February 27, 2025. I would, ...